Author

A. Lindgren

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:electrophysiology· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Hussainkhel· 2 shared A. J. Cutts· 2 shared A. Zenova· 2 shared C. Dehnhardt· 2 shared C. Dube· 2 shared E. Chang· 2 shared G. Bankar· 2 shared G. de Boer· 2 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

A. Hussainkhel

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

NaV1.6 inhibition drives the efficacy of voltage-gated sodium channel inhibitors to prevent electrically induced seizures in both wild type and Scn8aN1768D/+ gain-of-function mice

J. Johnson, T. Focken, P. K. Tari, C. Dube, S. J. Goodchild, J.-C. Andrez, G. Bankar, K. Burford, E. Chang, S. Chowdhury, J. Christabel, R. A. Dean, G. de Boer, C. Dehnhardt, W. Gong, , J. R. Empfield

The paper shows that inhibiting NaV1.6 reduces seizures in both wild-type and Scn8aN1768D/+ mice, suggesting NaV1.6 is a key target for anti-seizure drugs.

bioRxiv · Aug 3, 2023 · PreprintPharmacology & Toxicology

NBI-921352, a First-in-Class, Na V 1.6 Selective, Sodium Channel Inhibitor That Prevents Seizures in Scn8a Gain-of- Function Mice, and Wild-Type Mice and Rats

J. Johnson, T. Focken, K. Khakh, P. K. Tari, C. Dube, A. Williams, J.-C. Andrez, G. Bankar, D. Bogucki, K. Burford, E. Chang, S. Chowdhury, R. Dean, G. de Boer, S. Decker, , W

This paper describes NBI-921352, a selective NaV1.6 inhibitor that prevents seizures in Scn8a gain-of-function mice and wild-type models, with better efficacy and tolerability than existing antiseizure drugs.

bioRxiv · Aug 29, 2021Pharmacology & Toxicology